Literature DB >> 21620774

Extralimbic autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: an underdiagnosed entity?

Souhel Najjar1, Daniel Pearlman, Amanda Najjar, Vahid Ghiasian, David Zagzag, Orrin Devinsky.   

Abstract

Nonparaneoplastic glutamic acid decarboxylase antibody (GADAb)-related autoimmune encephalitis is a syndrome characterized by refractory seizures, progressive cognitive deficits, and psychiatric manifestations. The limbic subtype is well described, has characteristic affective and memory disturbances, and typical mesial temporal MRI abnormalities. We found only one single case report of the extralimbic subtype. We report clinical, radiological, and pathological findings of two additional cases with contrast-enhancing lesions. One of our cases presented as vasculitis, and the other imitated a tumor. Pathological evidence of both vasculitis and encephalitis has never been previously reported in any inflammatory condition affecting the brain. Our cases confirm prior reports that immune therapy can better control seizures associated with GADAb autoimmune encephalitis, and support the rationale for assaying for GADAb titers in patients with etiologically unclear extralimbic lesions and refractory epilepsy, independent of seizure types.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620774     DOI: 10.1016/j.yebeh.2011.03.038

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis.

Authors:  Divyanshu Dubey; Zehra Farzal; Ryan Hays; L Steven Brown; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2016-07-04       Impact factor: 6.570

Review 2.  Neuroinflammation and psychiatric illness.

Authors:  Souhel Najjar; Daniel M Pearlman; Kenneth Alper; Amanda Najjar; Orrin Devinsky
Journal:  J Neuroinflammation       Date:  2013-04-01       Impact factor: 8.322

3.  Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs.

Authors:  Kari-Matti Mäkelä; Aki Hietaharju; Antti Brander; Jukka Peltola
Journal:  Front Neurol       Date:  2018-07-13       Impact factor: 4.003

4.  Hippocampus and Insula Are Targets in Epileptic Patients With Glutamic Acid Decarboxylase Antibodies.

Authors:  Mercè Falip; Laura Rodriguez-Bel; Sara Castañer; Jacint Sala-Padró; Júlia Miro; Sónia Jaraba; Carlos Casasnovas; Francisco Morandeira; Javier Berdejo; Mar Carreño
Journal:  Front Neurol       Date:  2019-01-09       Impact factor: 4.003

5.  Immunotherapy-responsive Non-paraneoplastic Encephalitis with Antibodies against GAD, LGI1, and GABAA Receptor.

Authors:  Takahiro Nakano; Norio Chihara; Kento Matoba; Hisatsugu Tachibana; Shiho Okuda; Yoshihisa Otsuka; Takehiro Ueda; Kenji Sekiguchi; Hisatomo Kowa; Frank Leypoldt; Klaus-Peter Wandinger; Riki Matsumoto
Journal:  Intern Med       Date:  2021-07-30       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.